The twenty-ninth All-Russian research and practical conference "Intestinum 2018. Inflammation, motility, microbiome. Scientific achievements and medical practice" took place in December 2018. Within the framework of the conference, with the support of Valenta Farm Company and chaired by Vladimir T. Ivashkin, Chief Freelance Gastroenterologist of the Ministry of Health, Academician of the Russian Academy of Sciences, the symposium “Case management of irritable bowel syndrome - discussion of clinical recommendations. Modern concepts of human microbiota recovery” was held. The scientific program of the symposium included 6 lectures, which addressed issues of pathogenesis and diagnosis of irritable bowel syndrome (IBS), pharmacotherapy of this disease using probiotics, antacids, antispasmodics and other means, as well as features of the fight against IBS for multimorbid patients.
The report “Microbiota, short-chain fatty acids (SCFA) and its importance for bowel action” by Maria D. Ardatskaya, MD, professor of the Gastroenterology Department of the Central State Medical Academy of the Administrative affairs of the President of the Russian Federation caused a special interest of the symposium participants. She stressed in her report that IBS is in the first line of gastroenterological diseases, where intestinal dysbiosis turns out to be the basic pathogenetic factor. “The use the Lactitol (Exportal®) prebiotic is most efficient to influence the various links in a chain of many intestinal diseases. Metabolization of Lactitol comes with a greater production of butyric acid by 10 times compared with lactulose. Even low doses of Laktilol significantly improve gut microflora. A meta-analysis of Lactitol and lactulose two-arm studies in the treatment of constipation demonstrated that Lactitol is preferable to lactulose for the treatment of chronic constipation due to its higher efficacy as estimated by doctors, better organoleptic properties, better compliance and fewer adverse effects1.”
Lyudmila I. Butorova, Ph.D. (Medicine), Associate Professor of the Outpatient Therapy Department of the First Moscow State Medical University. n. a. I. M. Sechenov presented a report "Features of the therapy of duodenogastroesophageal reflux for multimorbid patient." The main objectives of bile reflux treatment in comorbid patients, where obesity appears to be the most common concomitant disease, include neutralizing the irritant effect of the components of the duodenal contents on the gastric and intestinal mucosa, as well as normalization of motor disorders in the gastroesophageal, duodenal zones and bile ducts.
Ludmila I. noted: "The leading agents in the fight against damaging effect of the components of the duodenal contents on the gastric and intestinal mucosa are considered to be proton pump inhibitors, ursodeoxycholic acid, sorbents, cytoprotectors, prokinetics and eukinetics. Antacids are an indispensable component of the therapy of such patients. Among this group of drugs, Antareit®, a new generation antacid, becomes increasingly popular with doctors. Innovative nonabsorbable form of antacid provides fast and prolonged antacid and long-term multitarget cytoprotective effect. The cytoprotective effect of Antareit® drug is associated with its ability to adsorb bile salts and its metabolites. In addition the anti-foam effect of the drug reduces gastric pressure, supporting normal motor-clearing function of the stomach."
The participants of the symposium gained not only an offing to listen to the lectures of leading experts in the field of gastroenterology, but also took part in a discussion during which they exchanged practical experience.
- 1J.of Indian Med. Assoc., 2010,, Nov.108(13), p, 789-792